泼尼松联合长春新碱治疗慢性免疫性血小板减少症的疗效及对细胞免疫功能的影响

doi:10.3760/cma.j.issn.1007-1245.2022.11.006

国际医药卫生导报 ›› 2022, Vol. 28 ›› Issue (11): 1504-1507.DOI: 10.3760/cma.j.issn.1007-1245.2022.11.006

泼尼松联合长春新碱治疗慢性免疫性血小板减少症的疗效及对细胞免疫功能的影响

林春燕张郧樊李丽羽陈琼黎巧茹

中山市人民医院儿科，中山　528400

收稿日期:2021-12-13 出版日期:2022-06-01 发布日期:2022-06-15
通讯作者: 黎巧茹，Email：qiaoru0422@163.com
基金资助:
广东省医学科学技术研究基金项目（B2020055）；

广东省中山市卫生健康局医学科研项目（2021A020516）

Efficacy of prednisone combined with vincristine in treatment of chronic immune thrombocytopenia and its influence on cellular immune function

Lin Chunyan, Zhang Yunfan, Li Liyu, Chen Qiong, Li Qiaoru

Department of Pediatrics, Zhongshan People's Hospital, Zhongshan 528400, China

Received:2021-12-13 Online:2022-06-01 Published:2022-06-15
Contact: Li Qiaoru, Email: qiaoru0422@163.com
Supported by:
Project Supported by Research Fund of Medical Science and Technology in Guangdong (B2020055);

Medical Scientific Research Project of Health Bureau in Zhongshan, Guangdong (2021A020516)

摘要/Abstract

摘要： 目的　研究泼尼松联合长春新碱治疗慢性免疫性血小板减少症的疗效及对细胞免疫功能的影响。方法　选取中山市人民医院2019年1月至2021年8月期间收治的136例慢性免疫性血小板减少症患儿为研究对象，进行前瞻性研究，按照随机数字表法等分为两组，分别予以不同的药物进行治疗。对照组中男33例，女35例，年龄（11.13±2.83）岁，采取泼尼松治疗；研究组中男34例，女34例，年龄（11.12±2.28）岁，在泼尼松治疗的基础上联合长春新碱治疗。持续治疗2个月后比较两组患者治疗前后的细胞免疫功能变化情况以及不同疗法的治疗效果和不良反应发生概率。使用SPSS 22.0统计软件分析数据，采用t、χ²检验。结果　治疗后，研究组的CD3⁺、CD4⁺、CD4⁺/CD8⁺分别为（54.87±4.59）%、（33.97±3.85）%、（1.85±0.36），均高于对照组［分别为（52.35±5.24）%、（31.03±3.70）%、（1.72±0.21）］，研究组CD8⁺为（23.78±2.38）%，低于对照组的（25.32±2.43）%，两组比较差异均有统计学意义（t=2.983、4.720、2.572、3.733，均P<0.05）。研究组患者的治疗有效率为94.12%（64/68），高于对照组的79.41%（54/68），两组比较差异有统计学意义（χ²=6.403，P=0.011）。两组不良反应发生情况差异无统计学意义（χ²=0.119，P=0.730）。结论　泼尼松联合长春新碱治疗慢性免疫性血小板减少症患儿具有较好的效果，并且对患儿的细胞免疫功能具有积极影响，值得广泛推广。

关键词: 泼尼松, 长春新碱, 慢性免疫性血小板减少症, 细胞免疫功能

Abstract:

Objective　To study the efficacy of prednisone combined with vincristine in the treatment of chronic immune thrombocytopenia and its effect on cellular immune function. Methods　One hundred and thirty-six children with chronic immune thrombocytopenia who were admitted to Zhongshan People's Hospital from January 2019 to August 2021 were selected for the prospective study, and were divided into a control group and a study group by the random number table method, with 68 cases in each group. The control group had 33 boys and 35 girls who were (11.13±2.83) years old, and they were treated with prednisone. The study group had 34 boys and 34 girls who were (11.12±2.28) years old, and they were treated with prednisone and vincristine. After continuous treatment for 2 months, the cellular immune function before and after the treatment, the treatment effects, and the incidences of adverse reactions in these two groups were observed and compared. The SPSS 22.0 statistical software was used to analyze the data. The t and χ² test were applied. Results　After the treatment, the CD3⁺, CD4⁺, and CD4⁺/CD8⁺ in the study group were (54.87±4.59)%, (33.97±3.85)%, and (1.85±0.36), which were higher than those in the control group [(52.35±5.24), (31.03±3.70)%, and (1.72±0.21)]; the CD8⁺ in the study group was (23.78±2.38)%, which was lower than that in the control group [(25.32±2.43)%]; there were statistical differences (t=2.983, 4.720, 2.572, and 3.733; all P<0.05). The effective rate in the study group was higher than that in the control group [94.12% (64/68) vs. 79.41% (54/68); χ²=6.403, P=0.011]. There was no statistical difference in the incidence of adverse reactions between the two groups (χ²=0.119, P=0.730). Conclusion　Prednisone combined with vincristine has a good effect in the treatment of children with chronic immune thrombocytopenia, and has a positive impact on their cellular immune function, so it is worth for widespread promotion.

Key words: Prednisone, Vincristine, Chronic immune thrombocytopenia, Cellular immune function

林春燕, 张郧樊, 李丽羽, 陈琼, 黎巧茹. 泼尼松联合长春新碱治疗慢性免疫性血小板减少症的疗效及对细胞免疫功能的影响[J]. 国际医药卫生导报, 2022, 28(11): 1504-1507.

Lin Chunyan, Zhang Yunfan, Li Liyu, Chen Qiong, Li Qiaoru. Efficacy of prednisone combined with vincristine in treatment of chronic immune thrombocytopenia and its influence on cellular immune function[J]. International Medicine and Health Guidance News, 2022, 28(11): 1504-1507.

参考文献

[1] 陈仕兵.部分脾栓塞术联合脾动脉灌注长春新碱治疗难治性血小板减少性紫癜和Evans综合征的长期疗效[J].介入放射学杂志,2011,20(8):610-612.DOI:10.3969/j.issn. 1008-794X.2011.08.006.

[2] 张秀安.人免疫球蛋白联合糖皮质激素治疗系统性红斑狼疮的临床效果观察[J].医学理论与实践,2021,34(16):2796-2798.DOI:10.19381/j.issn.1001-7585.2021.16.024.

[3] 丁乐,赵辉.吗替麦考酚酯联合糖皮质激素治疗难治性特发性血小板减少性紫癜的临床效果[J].临床医学研究与实践,2020,5(9):34-35.DOI:10.19347/j.cnki.2096-1413. 202009014.

[4] Patwardhan P, Proudman D, et al. Cost-minimization analysis comparing eltrombopag vs romiplostim for adults with chronic immune thrombocytopenia[J]. J Manag Care Spec Pharm, 2021,27(10):1447-1456. DOI: 10.18553/jmcp.2021.21080.

[5] 何继祥,姜义荣.利妥昔单抗联合地塞米松在治疗难治性特发性血小板减少性紫癜中的临床疗效及其安全性分析[J].中国现代药物应用,2019,13(13):120-121.DOI:10.14164/j.cnki.cn11-5581/r.2019.13.068.

[6] 杨青,宋元华,吕瑜,等.免疫抑制剂治疗儿童慢性免疫性血小板减少症的临床研究[J].中国医刊,2021,56(2):209-212.DOI:10.3969/j.issn.1008-1070.2021.02.028.

[7] 骆慧莎,陈汀劳,覃永亮,等.难治性免疫性血小板减少性紫癜患者应用小剂量利妥昔单抗联合IL-11治疗的临床效果探讨[J].中国医药科学,2019,9(3):213-216.DOI:10.3969/j.issn.2095-0616.2019.03.063.

[8] Fernández-Plaza S, González de Pablo J, Gálvez E, et al. Variables related to chronic immune thrombocytopenia: experience from a single center and comparison to a meta-analysis[J]. Eur J Pediatr, 2021,180(7):2075-2081. DOI: 10.1007/s00431-021-03990-8.

[9] 郭曼曼,汪怡.叶酸修饰长春新碱介孔二氧化硅脂质纳米粒体外抗肿瘤作用研究[J].山西中医,2020,36(10):54-56.DOI:10.3969/j.issn.1000-7156.2020.10.020.

[10] 郭毅刚,冯雪连,胡平,等.非血浆输入性血浆置换辅助治疗免疫性血小板减少性紫癜137例分析[J].湖北医药学院学报,2017,36(5):437-441,445.DOI:10.13819/j.issn.1006- 9674. 2017.05.011.

[11] 林军华,吴永明,金梅.大剂量甲基泼尼松龙冲击联合神经节苷脂治疗对急性脊髓炎患者的临床研究[J].重庆医学,2021,50(14):2433-2436.DOI:10.3969/j.issn.1671-8348. 2021.14.020.

[12] 张一弛,郝丽娜,王晓燕,等.泊沙康唑联合长春新碱致急性淋巴细胞白血病患者神经系统不良反应的病例分析[J].中国药学杂志,2021,56(06):502-506.

[13] 薛晓茹,胡金萍,王晓玲.长春新碱静脉注射无外渗致皮肤组织溃疡的原因及对策研究[J].西北国防医学杂志,2020,41(5):316-320.DOI:10.16021/j.cnki.1007-8622.2020. 05.012.

[14] 王锐,王相峰,宋燕青,等.联合应用地塞米松与长春新碱致急性B淋巴细胞白血病患儿急性继发性青光眼[J].药物不良反应杂志,2020,22(7):428-429.DOI:10.3760/cma.j.cn114015-20190220-00166.

[15] 刘迅,赵丽,陈力.长春新碱联合放线菌素D及环磷酰胺致严重肌肉及关节疼痛1例[J].中国药业,2020,29(18):93-95.DOI:10.3969/j.issn.1006-4931.2020.18.032.

[16] 司英健,杜振兰,陈伟,等.艾曲波帕与大剂量人免疫球蛋白联合激素治疗儿童慢性免疫性血小板减少性紫癜的疗效对比[J].西部医学,2022,34(01):69-73.

[17] 王樱澄,芮明军,商叶,等.地塞米松联合利妥昔单抗一线治疗成人慢性原发免疫性血小板减少症的经济性评价[J].中国药房,2021,32(24):3013-3018.DOI:10.6039/j.issn.1001-0408.2021.24.12.

[18] 刘晓,秦兰,李巍,等.补肾活血方对慢性特发性血小板减少性紫癜小鼠血小板功能的影响[J].世界中医药,2021,16(22):3337-3341.DOI:10.3969/j.issn.1673-7202.2021. 22.013.

[19] 李琦,康虹阳,范凌,等.骨化三醇联合西罗莫司治疗成人慢性原发免疫性血小板减少症的临床研究[J].中国实验血液学杂志,2021,29(06):1911-1916.DOI:10.19746/j.cnki.issn1009-2137.2021.06.038.

[20] 曾滟,杨思航,车虹,等.基于阴火理论辨治慢性原发免疫性血小板减少症[J].中国中医药信息杂志,2021,28(11):120-122.DOI:10.19879/j.cnki.1005-5304.202012131.

[21] 朱筱旌,马静瑶,谷昊,等.单中心儿童原发性慢性难治性免疫性血小板减少症临床特点分析[J].临床血液学杂志,2021,34(11):781-784.DOI:10.13201/j.issn.1004-2806. 2021.11.007.

[22] 余结盈,蒋文明.益气养阴止血方治疗儿童慢性原发免疫性血小板减少症临床观察[J].四川中医,2021,39(10):73-76.

[23] 王传芹,苏杰,王玉芬.不同阶段原发免疫性血小板减少症的临床疗效观察[J].中国临床研究,2021,34(9):1226-1228.DOI:10.13429/j.cnki.cjcr.2021.09.016.

[24] 杨思航,曾滟,赵冰洁,等.刘松山教授治疗慢性免疫性血小板减少症经验探析[J].四川中医,2021,39(6):7-9.

[25] 王丽媛,刘亢亢,储金华,等.儿童免疫性血小板减少症病程慢性化影响因素的研究[J].中国实验血液学杂志,2021,29(3):881-886.DOI:10.19746/j.cnki.issn1009-2137. 2021.03.036.

[26] 何东燕,彭哲,陈茂,等.桑菊饮加减治疗慢性免疫性血小板减少症1例[J].中国医药科学,2021,11(8):239-241. DOI:10.3969/j.issn.2095-0616.2021.08.064.

[27] 李蓉蔚,付荣凤,陈云飞,等.原发免疫性血小板减少症住院患儿临床分析[J].中国实验血液学杂志,2021,29(2):574-580.DOI:10.19746/j.cnki.issn1009-2137. 2021. 02.042.

[28] 陈娜,余惠平,许雪雪,等.扶正解毒方联合熊胆粉治疗儿童慢性免疫性血小板减少症[J].中医杂志,2020,61(23):2104-2106.DOI:10.13288/j.11-2166/r.2020.23.017.

[29] 尹萌萌,刘爱国,张艾,等.儿童慢性原发性免疫性血小板减少症[J].临床儿科杂志,2020,38(8):631-635.DOI:10.3969/j.issn.1000-3606.2020.08.018.

泼尼松联合长春新碱治疗慢性免疫性血小板减少症的疗效及对细胞免疫功能的影响

Efficacy of prednisone combined with vincristine in treatment of chronic immune thrombocytopenia and its influence on cellular immune function

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics